-
Pacritinib, sold
under the
brand name Vonjo, is an anti-cancer
medication used to
treat myelofibrosis. It is a
macrocyclic protein kinase inhibitor. It...
- the
original on 28
August 2022.
Retrieved 10
September 2022. "Vonjo (
pacritinib) Capsules, for Oral Use. Full
Prescribing Information" (PDF). CTI BioPharma...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- thrombocythemia)
myelofibrosis (MF). In
March 2022, the FDA
approved pacritinib (Vonjo) with an
indication to
treat adults who have
intermediate or high-risk...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
- (elatericin B, JSI-124) CYT387
Deuruxolitinib Lestaurtinib NSC-7908 NSC-33994
Pacritinib Peficitinib Ruxolitinib SD-1008
Tofacitinib (tasocitinib) JAK3 Cercosporamide...
